Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma

Eunjin Lee  
Samsung Medical Center

Ji Won Lee  
Samsung Medical Center  https://orcid.org/0000-0003-0084-1304

Boram Lee  
Samsung Medical Center

Kyunhee Park  
Samsung Medical Center

Joonho Shim  
Samsung Medical Center

Keon Hee Yoo  
Samsung Medical Center

Hong Hoe Koo  
Samsung Medical Center

Ki Woong Sung (✉ kwped@skku.edu)  
https://orcid.org/0000-0001-5989-4772

Woong-Yang Park  
Samsung Medical Center

Research article

Keywords: MYCN non-amplified neuroblastoma, tumour mutation burden, mutational signature, genomic profile, immunotherapy

Posted Date: May 10th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-26131/v1

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License

Version of Record: A version of this preprint was published on November 10th, 2020. See the published version at https://doi.org/10.1186/s12920-020-00819-5.
Abstract

Background MYCN amplification is the most important genomic feature in neuroblastoma (NB). However, limited studies have been conducted on the MYCN non-amplified NB including low- and intermediate-risk NB. Here, the genomic characteristics of MYCN non-amplified NB were studied to allow for the identification of biomarkers for molecular stratification.

Results Fifty-eight whole exome sequencing (WES) and 48 whole transcriptome sequencing (WTS) samples of MYCN non-amplified NB were analysed. Forty-one patients harboured WES and WTS pairs. In the MYCN non-amplified NB WES data, maximum recurrent mutations were found in MUC4 (26%), followed by RBMXL3 (19%), ALB (17%), and MUC16 and SEPD8 (14% each). Two gene fusions, CCDC32-CBX3 (10%) and SAMD5-SASH1 (6%), were recurrent in WTS analysis, and these fusions were detected mostly in non-high-risk patients with ganglioneuroblastoma histology. Analysis of risk-group-specific biomarkers showed that several genes and gene sets were differentially expressed between the risk groups, and some immune-related pathways tended to be activated in the high-risk group. Mutational signatures 6 and 18, which represent DNA mismatch repair (MMR) associated mutations, were commonly detected in 60% of the patients. In the tumour mutation burden (TMB) analysis, four patients showed high TMB (> 3 mutations/Mb), and had mutations in genes related to either MMR or homologous recombination. Excluding four outlier samples with TMB > 3 Mb, high-risk patients had significantly higher levels of TMB compared with the non-high-risk patients.

Conclusions This study provides novel insights into the genomic background of MYCN non-amplified NB. Activation of immune-related pathways in the high-risk group and the results of TMB and mutational signature analyses collectively suggest the need for further investigation to discover potential immunotherapeutic strategies for NB.

Background

Neuroblastoma (NB), the most common extracranial solid tumour in children, accounts for 6 to 10% of all childhood cancers. NB arises from precursor cells of the sympathetic nervous system and adrenal medulla [1]. The clinical course is highly heterogeneous, ranging from spontaneous regression without therapeutic intervention to rapid progression to death, despite modern intensive multimodal treatment regimens. Thus, clinical and biological factor-based risk stratification and tailored treatment approaches have been the mainstay of NB treatment. International Neuroblastoma Risk Group (INRG) defines the high-risk group to include patients with MYCN amplified tumours and patients > 18 months old with metastatic tumours [2].

Amplification of the MYCN oncogene is the first genetic marker reported to indicate highly aggressive and advanced-stage NB. It is observed in approximately 20% of cases and remains a powerful prognostic factor, indicating adverse clinical outcomes [3]. The clinical features of MYCNamplified NB have been attributed to the biological consequence of MYCN amplification. MYCN-amplified tumours make up about 40% of high-risk NBs [4], indicating that 60% of high-risk NBs are MYCN non-amplified tumours. Despite the extensive study of the genomic characteristics of high-risk NB including MYCN-amplified tumours [4–6], genomic profiling of MYCN non-amplified NB, including low- and intermediate-risk NB, has been limited.

Immunotherapy, which includes the use of immune checkpoint inhibitors, has become a potential therapeutic option, especially in adult oncology. However, except for a monoclonal antibody that acts against the tumour-associated disialoganglioside, GD2 [7], little is known about immunotherapy in NB. Here, we examined the genomic profiles of MYCN non-amplified NB and studied risk-group-specific biomarkers, tumour mutational burden (TMB), and mutational signature to identify biomarkers for the molecular stratification of NB.

Results

Mutational landscape of MYCN non-amplified NB

WES and WTS were conducted for 70 NB samples. QC filtering and removal of MYCN-amplified NB patient data yielded 58 WES and 48 WTS samples (Fig. 1a). Thirty-five patients (53.8%) were diagnosed as metastatic, and 26 patients (40%) were classified into the high-risk group. The median age was 3.1 years, with a range of 0 to 14.9 years (Table 1).
Table 1
Demographics of study populations for WES and WTS analysis

|                          | All (n = 65) | WES (n = 58) | WTS (n = 48) |
|--------------------------|-------------|--------------|--------------|
| **Sex, No. (%)**         |             |              |              |
| Male                     | 30 (46.2)   | 25 (43.1)    | 25 (52.1)    |
| Female                   | 35 (53.8)   | 33 (56.9)    | 23 (47.9)    |
| **Age, median years (range)** | 3.1 (0 ~ 14.9) | 3.35 (0 ~ 14.9) | 2.7 (0 ~ 10) |
| **Age, No. (%)**         |             |              |              |
| < 18 months              | 18 (27.7)   | 11 (19.0)    | 16 (33.3)    |
| ≥ 18 months              | 47 (72.3)   | 47 (81.0)    | 32 (66.7)    |
| **Stage, No. (%)**       |             |              |              |
| Localized                | 30 (46.2)   | 27 (46.6)    | 24 (50.0)    |
| Metastatic               | 35 (53.8)   | 31 (53.4)    | 24 (50.0)    |
| **Risk Group, No. (%)**  |             |              |              |
| High-risk                | 26 (40.0)   | 26 (44.8)    | 16 (33.3)    |
| Non-high risk            | 39 (60.0)   | 32 (55.2)    | 32 (66.7)    |
| **Pathology, No. (%)**   |             |              |              |
| Undifferentiated         | 1 (1.5)     | 1 (1.7)      | 1 (2.1)      |
| Poorly differentiated     | 25 (38.5)   | 21 (36.2)    | 19 (39.6)    |
| Differentiating          | 13 (20.0)   | 11 (19.0)    | 9 (18.8)     |
| Ganglioneuroblastoma (GNB) | 26 (40.0)   | 25 (43.1)    | 19 (39.6)    |

WES data of 58 patients were analysed. The median number of variants per sample was 34.5, with a range of 11–537 (Additional file 1: Figure S1A). A total of 2,601 genes were mutated in at least one sample (Additional file 1: Figure S1B). The most frequently mutated gene, **MUC4**, was found to be mutated in 26% of samples, followed by **RBMXL3** (19%), **ALB** (17%), **MUC16** (14%), and **SEPD8** (14%) (Fig. 1b). In comparison with 9 **MYCN**-amplified tumours, there was no statistically significant difference between the mutation frequencies of single genes (Fig. 1c). However, mutations in mucin family genes such as **MUC4**, **MUC16**, and **MUC17** were more frequent in **MYCN** non-amplified subjects.

Gene fusions predicted by three or more algorithms were considered to be true positives. Among 48 samples, 21 gene fusions were detected in 15 samples (Table 2). **CCDC32-CBX3** fusion recurred in five samples, while **SAMD5-SASH1** fusion recurred in three samples (Additional file 2: Figure S2A). The existence of recurrent fusions was verified by Sanger sequencing. These two recurrent fusions were detected only in ganglioneuroblastoma (GNB) histology. Most of the recurrent fusions were detected in non-high-risk patients, aside from one patient who had four other fusions, including **CCDC32-CBX3** and **SAMD5-SASH1** fusions. In patients with **SAMD5-SASH1** fusion, **SAMD5** and **SASH1** were upregulated; however, this correlation was not observed in **CCDC32-CBX3** fusion (Additional file 2: Figure S2B).
### Table 2
List of patients with gene fusions

| Risk group | ID       | Sex | Age | Stage  | Pathology | Chromosomal abnormality | Event      | Fusion                                                                 |
|------------|----------|-----|-----|--------|-----------|--------------------------|------------|------------------------------------------------------------------------|
| High risk  | N_SMC_001| M   | 3.8 | Metastatic | GNB      | 11q                       | Recur/Dead | LUC7L3:KLC2                                                             |
|            | N_SMC_006| M   | 3.1 | Metastatic | PD       | 11q                       | Recur      | CNTNAP4:RAB11FIP4                                                      |
|            | N_SMC_011| M   | 3.3 | Metastatic | GNB      |                           |            | CCDC32:CBX3*                                                            |
|            |          |     |     |         |           |                           |            | SAMD5:SASH1$                                                            |
|            |          |     |     |         |           |                           |            | HLA-C:HLA-A                                                            |
|            |          |     |     |         |           |                           |            | L1RAPL1:REPS2                                                           |
|            | N_SMC_017| M   | 2.3 | Metastatic | D        | 11q 17q                   |            | PPFIA1:GSDMA                                                           |
|            | N_SMC_046| M   | 5.3 | Metastatic | PD       | 1p                        |            | RALGPS2:DNAJC8                                                          |
|            | N_SMC_049| M   | 6.1 | Metastatic | PD       | 11q                       |            | RPN1:CCDC58                                                            |
|            | N_SMC_070| F   | 4.6 | Metastatic | UD       | 17q                       |            | FBXL7:CDKN3                                                            |
|            | N_SMC_076| M   | 3.8 | Metastatic | PD       | 1p 11q 17q                |            | HP1BP3:NUP85                                                            |
|            |          |     |     |         |           |                           |            | MED8:ELOVL1                                                            |
| Non-high risk | N_SMC_003| M   | 10  | Localized | GNB      | 1p                        |            | CCDC32:CBX3*                                                            |
|            | N_SMC_026| F   | 4.1 | Localized | GNB      |                           |            | CCDC32:CBX3*                                                            |
|            | N_SMC_034| F   | 2.6 | Localized | D        | 17q                       |            | CCDC32:CBX3*                                                            |
|            |          |     |     |         |           |                           |            | KCNH7:MAP3K19                                                           |
|            |          |     |     |         |           |                           |            | PPP6R2:ANKIB1                                                           |
|            | N_SMC_060| M   | 0.1 | Localized | D        | 11q                       |            | MX1:FAM3B                                                              |
|            | N_SMC_085| F   | 2.1 | Localized | GNB      | 17q                       |            | CCDC32:CBX3*                                                            |
|            | N_SMC_089| M   | 3.5 | Localized | GNB      |                           |            | SAMD5:SASH1$                                                            |
|            | N_SMC_093| F   | 6.4 | Localized | GNB      |                           |            | SAMD5:SASH1$                                                            |

UD, undifferentiated; PD, poorly differentiated; D, differentiating; GNB, ganglioneuroblastoma

There are two recurrent fusions *CCDC32:CBX3* $SAMD5:SASH1$  

### Identification of risk-group specific biomarkers

An association between risk groups and genomic variants was not observed (Additional file 3: Figure S3A). To identify the associations between altered pathways and risk groups, 17,810 annotated gene sets were analysed, and mutation status was determined in each pathway using MSigDB v6.2. Among 7,044 pathways acquired from the BIOCARTA, KEGG, REACTOME, and Gene Ontology (GO) databases, 48 pathways had a P-value < 0.05 in Fisher’s exact test that became insignificant after multiple FDR corrections (Additional file 3: Figure S3B). Alterations in metabolic pathways were enriched in the high-risk group.

Further, WTS data of 48 patients showed a correlation between gene expression patterns and the risk-group identity (Additional file 4: Figure S4A). Eighty-six genes (46 in the high-risk group and 40 in the non-high-risk group) showed statistically significant overexpression (P-value < 0.05 and absolute fold change > 2) (Fig. 2a and Additional file 4: Figure S4B). *FAM153A (SAMD15)* and *FAM15B (TMED8)* were the most significantly over-expressed genes in the high-risk group.
The GSVA score was computed for 17,810 gene sets, and an association test was performed for differentially expressed gene sets between high- and non-high-risk groups (Additional file 5: Figure S5A). In total, 44 gene sets were significantly different between the risk groups (P-value < 0.05 and absolute mean difference > 0.3) (Fig. 2b and Additional file 5: Figure S5B). The gene sets did not differ in most of the acquired canonical pathways; only 15 of these pathways showed statistically significant differences (Additional file 5: Figure S5C). In the high-risk group, the pathways of ketone body metabolism and mitochondrial fatty acid beta oxidation were inactivated, while the pathways of TALL-1, regulation of MHC class II biosynthesis, and regulation of interferon gamma secretion were activated (Additional file 5: Figure S5D). The ganglioside biosynthesis pathway showed correlations with risk group identity and GNB histology (P-value = 0.0002) (Additional file 5: Figure S5E).

**Analyses of mutational signature and tumour mutation burden (TMB)**

A mutational signature analysis was performed with WES data (Additional file 6: Figure S6A). Each sample was assigned to the most predominant signature among the 30 signatures (MS-1 to MS-30). Sixty percent of samples were assigned to either MS-15 or MS-6, which were denoted as MMR signatures (Fig. 3a). Association was not found between MMR signatures and mutation incidence in MMR-related genes such as MLH1, MSH2/6, or PMS2. Only five samples (5.58%) were assigned to MS-18, a known NB signature. The association between MS-15 and GNB histology was identified (P-value = 0.0012) (Fig. 3b).

The median TMB was 0.66 Mb (Fig. 3c) in all patients; the specific median values were 1.04 Mb in the high-risk group and 0.53 Mb in the non-high-risk group (P-value = 0.195). Excluding four outlier samples with TMB > 3 Mb, high-risk patients had significantly higher TMB compared with the non-high-risk patients (0.95 Mb vs 0.60 Mb, P-value = 0.001) (Fig. 3d). Among the four patients whose tumours had TMB > 3 Mb, two patients belonged to the high-risk group and the other two belonged to the non-high-risk group. One sample from the high-risk group, having two missense mutations (Q1285K and T290K) in POLE and one missense mutation (G357W) in MLH1, showed a high TMB value of 10.66 Mb. Another high-risk patient with a high TMB value of 3.83 Mb had mutations in ATR, ATRX, POLQ, RAD54L, and SPIDR, all of which play roles in DNA repair or homologous recombination. Further, two samples from the non-high-risk group showed relatively high TMB, at 5.1 Mb and 4.33 Mb. Both patients were diagnosed at a very young age (under two months). Although the tumours of both patients showed high microsatellite instability (MSI), their underlying mutation profiles were different—POLE splicing variant was detected in one patient, while the other patient had deleterious mutations in RAD51AP1, RAD51B, and RMI2, which are involved in homologous recombination deficiency.

In terms of the association between TMB and mutational signatures, the sample with extremely high TMB (> 10 Mb) showed MS-18, while the three samples with relatively high TMB (> 3 Mb) showed MS-6, one of the four MMR signatures. (Fig. 3e and Additional file 6: Figure S6B).

**Discussion**

The genomic characteristics of MYCN non-amplified NB were identified in this study using WES and WTS. MYCN-amplified NB was excluded, because MYCN amplification is a well-known prognostic factor in NB, and gene expression in MYCN-amplified NB is quite different from that in MYCN-non-amplified NB. A total of 26 high-risk patients were without MYCN amplification, and these patients accounted for 40% of all MYCN-non-amplified patients in our dataset.

Common variants of high-risk NB, such as ALK, ATRX, PTPN11, NRAS, and MYCN mutations [5], were not noticeable. Instead, after eliminating the effect of MYCN amplification and considering low-VAF mutations, a number of novel recurrently mutated genes were found. Although the recurrent mutations did not show strong patterns of association with the different risk groups, their roles in MYCN-non-amplified NB warrant further exploration. The mutation profiles of MYCN-amplified and non-amplified patients were compared, and mutations in mucin family genes were found to be more frequent in the MYCN-non-amplified subjects. Although mutations in the mucin gene family have been reported in NB [8], their biological relevance to NB remains unclear.

Two recurrent fusions, CCDC32-CBX3 and SAMD5-SASH1, were newly detected in this study. No recurrent fusion has been reported in NB, with the exception of fusions including the NBAS gene in MYCN-amplified tumours [5]. All but one of the patients
in this study who presented recurrent fusions fell under the non-high-risk category; thus, it is likely that these fusions have not been reported because most of the previous studies included only high-risk patients. These fusions have been detected in other cancers [10, 11] and further research is needed to investigate the potential roles of these fusions in the tumorigenesis of NB.

In the analysis of risk-specific biomarkers, several genes and gene sets were differentially expressed between the risk groups. Specifically, some immune-related pathways, such as regulation of MHC class II biosynthesis and regulation of interferon gamma secretion, tended to be activated in the high-risk group. In this study, high-risk patients had higher TMB values compared with the non-high-risk patients (when four outlier samples with TMB > 3 Mb were excluded), which could be a factor that causes the activation of immune-related pathways in the high-risk group. The underlying mechanism of this finding remains to be elucidated.

Notably, this study presents several findings in support of the possible application of immunotherapy in NB. In the TMB analysis, a subset of patients was found to have much higher TMB values than the other patients. One sample had TMB > 10 Mb, and three more had a moderate threshold of > 3 Mb. All four of these tumours had mutations in DNA mismatch repair deficiency-related genes or genes involved in homologous recombination deficiency. MSI was high in the two non-high-risk patients. Additionally, in the mutation signature analysis, 65% of tumours showed MMR signatures when each sample was designated to the most predominant signature out of all 30 signatures. PD-1/L1 expression, TMB, and MSI have been considered as predictive biomarkers for immunotherapy in many studies [12–16], and the findings of this study suggest the possibility of immunotherapy introduction in a subset of patients with NB.

Despite comprehensive analysis, this study has several limitations. In mutational signature analysis, MS-18, a known NB signature, was present in only a few samples. Mutational signatures were calculated based on a pattern of 96 base substitution combinations, so an insufficient number of mutations may have affected the analysis. The median number of mutations, at 34.5, was relatively small. Therefore, the mutational signatures of patients with lower numbers of variants may fail to represent all of the characteristics. Since the number of variants and TMB in childhood cancers are smaller compared to those in adult cancers [17–21], the results of mutational signature analysis need to be interpreted with caution. Furthermore, MSigDB contains pathways with large numbers of genes, and the pathways investigated here had gene sets with up to hundreds of genes. Therefore, it is necessary to verify the effects of individual mutations.

Conclusions

In conclusion, this study provides novel insights into the genomic background of the MYCN-non-amplified NB population. Activation of immune-related pathways in the high-risk group and the results of TMB and mutational signature analyses collectively suggested the need for further investigation to discover potential immunotherapeutic strategies for NB.

Methods

Study population and data collection

From November 2015, tissue and blood samples were collected prospectively from NB patients undergoing biopsy. Samples from patients who were diagnosed before November 2015 that had been deposited at the Samsung Medical Center Biobank were also included. Medical records regarding age, sex, stage, risk group, pathology, and outcome were collected. Tumour staging was determined by following the International Neuroblastoma Staging System standards [2]. MYCN amplification was determined by performing interphase fluorescence in situ hybridization on tumour tissues. Patients older than 18 months and in stage four malignancy and patients with MYCN-amplified tumours were stratified as high-risk patients.

DNA and RNA extraction

All tumour specimens were reviewed by a pathologist to determine the percentage of viable tumours and their adequacy for sequencing. Genomic DNA from the tissue and blood was extracted using a QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA). The total RNA from the same fresh frozen tumour tissues was extracted with an RNeasy Mini Kit (Qiagen, Valencia, CA, USA),
according to the manufacturer's instructions. The quality and quantity of extracted nucleic acids were evaluated using Nanodrop 8000 UV-Vis spectrometer (Nanodrop Technologies Inc., Wilmington, DE, USA), Qubit® 3.0 Fluorometer (Life technologies Inc., Carlsbad, CA, USA) and 4200 TapeStation (Agilent Technologies Inc., Santa Clara, CA, USA). Specimens with a yield over 100 ng were selected for whole exome sequencing (WES) and whole transcriptome sequencing (WTS). Those with a median DNA fragment size of 350 bp and an RNA integrity number (RIN) of 5 were selected.

**WES and variant calling**

Tumour and matched normal DNA were enriched for exon regions, using the SureSelect XT regent kit (Agilent Technologies Inc., Santa Clara, CA, USA) and SureSelect XT Human All Exon V5 kit (Agilent Technologies Inc., Santa Clara, CA, USA). The libraries were pooled, denatured, and sequenced in 100-bp paired-end mode using the HiSeq Rapid SBS Kit v2 (200 Cycles) and HiSeq® Rapid PE Cluster Kit v2 in Illumina HiSeq 2500 platforms (Illumina Technologies Inc., San Diego, CA, USA). The mean target coverages were 166x in tumours and 104x in normal blood. Reads were aligned to the human reference genome (hg19) using the Burrows-Wheeler Alignment tool (BWA) version 0.7.5a [22]. Sequence Alignment and Mapping (SAM) les were converted to Binary Alignment and Mapping (BAM) les using SAMtools (v0.1.19) [23]. Duplicate reads were removed using Picard (version 1.128), base quality was recalibrated, and local realignment was optimized using The Genome Analysis Toolkit (GATK) version 3.5 [24]. Single nucleotide variants (SNVs) and indels were identified using MuTect2 version 3.8.0 [25], Strelka2 version 2.8.2 [26], and Pindel version 0.2.5b9 [27]. Germline variants were identified using HaplotypeCaller version 3.8.0 [28]. Variants were annotated using Ensembl Variant Effect Predictor (VEP) version 87 [29]. Variants located in exons with sufficient coverage (minimum depth of coverage ≥ 8) and a significant variant allele frequency (VAF ≥ 1%) were chosen for further statistical analyses. Synonymous variants were filtered out. Read alignments were manually examined using Integrative Genomic Viewer (IGV) (http://www.broadinstitute.org/igv/).

**WTS and data processing**

Sequencing libraries were prepared using TruSeq RNA Sample Preparation kit v2 (Illumina Technologies Inc., San Diego, CA, USA). RNA libraries were sequenced in 100-bp paired-end mode using TruSeq Rapid PE Cluster kit and TruSeq Rapid SBS kit v2 in Illumina HiSeq 2500 (Illumina Technologies Inc., San Diego, CA, USA). Unresolved bases in FASTQ files were trimmed, reads were aligned to the human reference genome, hg19, using TopHat version 2.0.6 [30], and reference-guided assembly of transcripts was performed using Cufflinks version 2.1.1 [31]. Alignment quality was verified with SAMtools version 0.1.19 [23]. Gene expression was estimated from the RNASeq data of 56 patients using a count-based method with RSEM [32]. In total, 20,345 protein-coding genes were selected. Further, genes that were expressed in at least three samples were retained. A total of 16,120 genes were analysed. Gene counts were used as the input for Trimmed Mean of M value (TMM) normalization in the R package, edgeR [33], and normalized counts were transformed to log2-counts per million (logCPM) using the voom application in the R package, limma [34].

Gene fusions were predicted by several algorithms, such as ChimeraScan [35], deFuse [36], FusionMap [37], MapSplice [38], and TopHat [30]. Fusions predicted by more than three algorithms were considered further. The putative fusions were manually investigated using IGV.

**Validation of fusions by RT-PCR and Sanger sequencing**

The putative gene fusions, detected by RNA-Seq, were verified by reverse transcription PCR (RT-PCR), followed by Sanger sequencing. cDNA was synthesized from 2 μg total RNA using a QuantiTect Reverse Transcription kit (Qiagen Inc., Hilden, Germany) with primers that flank the breakpoint of the fusion, in DNA Engine Tetrad 2 Peltier Thermal Cycler (BIO-RAD, Hercules, CA, USA) with the following cycling conditions: one cycle of 5 minutes at 95 °C, followed by three-step cycles of 30 seconds at 95 °C, 30 seconds at 62 °C, 10 minutes at 72 °C, and a final extension for 20 minutes at 72 °C. PCR products were purified using a Multiscreen filter plate (Millipore Corp., Bedford, MA, USA) and sequenced in an ABI prism 3730XL Analyzer (Thermo Fisher Scientific, Waltham, MA, USA) using a BigDye (R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems Inc., Foster City, CA, USA). The results were accessed by Variant Reporter Software v 1.1 (Applied Biosystems Inc., Foster City, CA, USA).

**Mutational signatures and tumour mutation burden (TMB)**
A set of 30 mutational signatures, which represent distinct characteristics of human cancer types based on base substitutions at the site of mutation, was obtained [17]. To calculate mutational signatures from each sample, deconstructSigs (R package) was used, and the weighted combination of predefined signatures was identified to comprehend the mutational profiles [39].

TMB, defined as the number of somatic variants per megabase (Mb), was calculated by dividing the total number of mutations from WES by the size of the target coding region.

**Gene-set enrichment analyses (GSEA)**

Gene-set enrichment analyses (GSEA), based on gene expression data for each sample, were performed using R package, GSVA [40] on 17,810 annotated gene sets from the Molecular Signatures Database (MSigDB v6.2, http://software.broadinstitute.org/gsea/msigdb/index.jsp).

**Statistical analyses**

All statistical tests were performed using R software v.3.4.2 (https://www.r-project.org/). The associations between risk-group and genomic information, including the frequency of mutation, TMB, mutational signature, gene expression, and gene-set expression, were examined using the T-test or Fisher’s exact test. Multiple test correction with false discovery rate (FDR) was applied to the expression data analyses. P-value < 0.05 was considered as significant.

**Abbreviations**

- MMR: mismatch repair
- MS: mutational signature
- MSI: microsatellite instability
- NB: neuroblastoma
- TMB: tumour mutation burden
- WES: whole exome sequencing
- WTS: whole transcriptome sequencing

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of Samsung Medical Center (IRB approval no. SMC 2015-11-053), and written informed consent was obtained from all of the participants and/or their parents or legal guardians.

**Consent for publication**

Not applicable

**Availability of data and materials**
The dataset supporting the conclusions of this article is available in the NCBI Sequence Read Archive repository under accession number PRJNA592880, [https://www.ncbi.nlm.nih.gov/sra/PRJNA592880].

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (No. 1520210) and a grant from the National Research Foundation of Korea (NRF) funded by the Korean government (NRF-2017R1A2B4008178).

**Authors’ contributions**

EL and JWL contributed to the conception and design of the study. BL, KP, and JS developed the bioinformatics pipeline and processed data for the analysis. EL, KHY and HHK analysed the data. EL and JWL wrote the manuscript. KWS and WYP revised the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

The authors are grateful to the patients, and to the doctors and nurses at Samsung Medical Center. We also thank our colleagues for their technical support in data generation.

**References**

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma Lancet. 2007;369:2106–20.
2. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–97.
3. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121–4.
4. Peifer M, Hertwig F, Roels F, Driendax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700–4.
5. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45:279–84.
6. Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015;47:1411–4.
7. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.
8. Miller AL, Garcia PL, Pressey JG, Beierle EA, Kelly DR, Crossman DK, et al. Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors. Sci Rep. 2017;7:17787.
9. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874–85.
10. Sa JK, Lee IH, Hong SD, Kong DS, Nam DH. Genomic and transcriptomic characterization of skull base chordoma. Oncotarget. 2017;8:1321–8.

11. Zhu C, Wu L, Lv Y, Guan J, Bai X, Lin J, et al. The fusion landscape of hepatocellular carcinoma. Mol Oncol. 2019;13:1214–25.

12. Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44–56.

13. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017;16:2598–608.

14. Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017;36:179–90.

15. Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clin Cancer Res. 2017;23:4970–9.

16. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14:847–56.

17. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.

18. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.

19. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555:321–7.

20. Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, et al. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. Oncologist. 2017;22:1478–90.

21. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018;555:371–6.

22. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–60.

23. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078–9.

24. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.

25. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9.

26. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012;28:1811–7.

27. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009;25:2865–71.

28. Poplin R, Ruano-Rubio V, DePristo MA, Fennell TJ, Carneiro MO, Van der Auwerda GA, et al. Scaling accurate genetic variant discovery to tens of thousands of samples. bioRxiv. 2018:201178.

29. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thorpe TM, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.

30. Kim D, Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 2011;12:R72.

31. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511–5.

32. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.
33. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40.

34. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29.

35. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics. 2011;27:2903–4.

36. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol. 2011;7:e1001138.

37. Ge H, Liu K, Juan T, Fang F, Newman M, Hoeck W. FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. Bioinformatics. 2011;27:1922–8.

38. Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 2010;38:e178.

39. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;17:31.

40. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

Figures
Figure 1

(a) Consort flow of study population. (b) Somatic mutation profiles of WES data. MYCN-amplified patients (n = 9), presented on the right side of the heatmap (purple), were compared with the non-amplified population. The top 20 frequently mutated genes (green bar) and 5 functional genes (orange bar) related to DNA mismatch repair or homologous recombination repair are listed. *TMB: Tumour Mutational Burden. (c) Comparison of incidence of mutation between MYCN-amplified and non-amplified groups.
Figure 2

(a) Profiles of differentially expressed genes (n=86) between high- and non-high-risk groups. (b) GSVA score of gene sets significantly associated with risk group (n=44).
Figure 3

(a) Distribution of predicted mutational signature (MS), which was predominantly presented in each sample. The proportion of samples showing MS-15 (46.6%), MS-6 (13.8%), and MS-18 (8.6%) is presented. (b) Association between signatures and clinical pathology. The size of each circle represents the number of samples. MS-15 and ganglioneuroblastoma (GNB) histology had a significant association (P-value = 0.0012). (c) Distribution of Tumour Mutation Burden (TMB; n = 58). (d) Comparison of TMB between high-risk (n = 26) and non-high-risk (n = 32) groups with/without high TMB patients (n = 4). (e) Correlation between mutational signature weights and TMB. One hyper-mutated sample (TMB > 10) showed MS-18, and three samples with moderate high TMB showed MS-6.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile3.pdf
- Additionalfile6.pdf
- Additionalfile5.pdf
• Additionalfile2.pdf
• Additionalfile4.pdf
• Additionalfile1.pdf